心血管疾病一直是威胁全世界人民健康的重要疾患，2011年世界卫生组织发布首份《全球非传染性疾病现状报告》，数据显示全球每年约有1730万人死于心血管疾病，占全球死亡总数的30.35%。到2014年第二份报告发布，死亡人数依然高至1750万，占全球死亡总数31.25%。在中国，致命的三种疾病是脑卒中、冠心病以及慢性阻塞性肺病，这三种疾病造成的死亡人数占2013年全部死亡人数的46%。而以世界卫生组织的定义，心血管病是心脏和血管疾患引起的，包括冠心病、脑卒中、高血压、心衰等。换言之，中国致命三大健康杀手，心血管疾病占去两个。
Cardiovascular diseases have always been an important disease threatening people's health all over the world. In 2011, the world health organization issued the first "global status report on non-communicable diseases" data showed that about 17.3 million people died of cardiovascular diseases every year, accounting for 30.35% of the global total. By 2014, when the second report was released, the death toll was still as high as 17.5 million, 31.25% of the global total. The three deadliest diseases in China are stroke, coronary heart disease and chronic obstructive pulmonary disease, which accounted for 46% of all deaths in 2013. According to the world health organization, cardiovascular diseases are caused by heart and vascular diseases, including coronary heart disease, stroke, hypertension and heart failure. In other words, cardiovascular disease accounts for two of China's top three killers.
据中国国家心血管病中心发布的《中国心血管病报告2012》数据显示，中国心血管病现患人数已高达2.9亿，即每10个成年人中就有2人患心血管病，每年约350万人死于心血管病，相当于每10秒就有1人死于心血管病。而另一个由国家心血管病中心联合阜外心血管病医院组织实施的临床研究显示，在中国，心血管病患者的住院人数在2001年至2010年的十年间增加了四倍多。2001年因心脏病住院的平均每十万人中有3.7人，到2010年就飙升至15.8人。
According to the data of China cardiovascular disease report 2012 released by China national cardiovascular disease center, the number of people suffering from cardiovascular disease in China has reached 290 million, that is 2 out of 10 adults suffer from cardiovascular disease, and about 3.5 million people die of cardiovascular disease every year, which is equivalent to 1 person dying of cardiovascular disease every 10 seconds. Another clinical study, conducted by the national center for cardiovascular disease and the fuwai cardiovascular hospital, showed that the number of hospitalizations for cardiovascular diseases in China more than quadrupled between 2001 and 2010. In 2001 there were 3.7 hospitalizations for heart disease per 100, 000 people, but by 2010 there were 15.8.
英国和欧洲在医疗器械领域非常发达，拥有很多世界知名品牌的医疗器械，在科研领域也是引领世界发展趋势。本公司已经与一家位于牛津的公司 Oxford Cardiomox Ltd 签署了代理合作协议，负责在中国广西推广该公司的核心产品：Cardiomox心磁图仪。为了更好地进行合作和市场推广，以及售后服务和技术支持，我公司派驻了一名高级商务代表常驻英国，并在英国设立新的欧洲办事处，负责与牛津公司进行业务联系和对接合作事宜。此外，我公司还将不断从英国和欧洲范围内引进更多更先进的医疗技术和器械设备，促进中国和英国与欧洲在先进的医疗器械领域的交流与合作。
UK and Europe are very developed in the field of medical devices, with many world-renowned brands of medical devices, and lead the world development trend in the field of scientific research. Our company has signed a cooperation agreement with an oxford-based company, Oxford Cardiomox Ltd., to promote its core product, the Cardiomox Magnetocardiograph (MCG), in Guangxi, China. In order to better carry out cooperation and marketing, as well as after-sales service and technical support, our company appointed a senior business representative to the UK, and set up a new European office in the UK, responsible for business contact and cooperation with Oxford company. In addition, we will continue to introduce more and more advanced medical technology and equipment from the UK and Europe, and promote the exchanges and cooperation between China, the UK and Europe in the field of advanced medical equipment.
牛津Cardiomox公司，心脏病诊断领域的先驱，提出了一种用于心脏病早期诊断的新型医学方法，在心磁图仪（MCG）临床研究历史的基础上，结合智能软件的发展，为市场提供了一种非常灵敏和非侵入性的解决方案，创新的Cardiomox MCG-9心磁图仪，它能够快速准确地诊断心肌缺血和心律失常等心脏疾病，是心脏病学的开创性诊断创新。
Oxford Cardiomox Ltd, a pioneer in heart disease diagnostics, proposes a novel medical approach for early diagnosis of heart conditions. Building on along history in clinical research on Magnetocardiography (MCG) in conjunction with intelligent software developments, with its innovation product Cardiomox MCG-9 allows early cardiovascular diagnosis and bringing to the market a very sensitive and non-invasive solution to enable rapid and accurate diagnostic of cardiac conditions such as myocardial ischemia and arrhythmia, it is a pioneering diagnostic innovation in Cardiology.
Functional imaging, providing detailed electrophysiological physiological maps of the heart for a robust diagnostic procedure at an early stage of disease.
Rapid and Safe, our simple and non-invasive procedure is performed without contact to the patient allowing rapid (10 min) patient processing.
Robust Diagnosis Aid, with the unique supporting intelligent and user friendly software, Cardiomox’s innovation provides a robust functional diagnosis.
新一代磁心造影技术使用一种强大的医疗设备来检测心肌细胞发出的微弱电流信号。该方法快速、简便、无创。结合智能软件，它允许生成电流密度矢量图像显示心脏的电生理状态。由于它的高灵敏度，这种方法允许检测目前心脏疾病的异常症状，在休息时，使心脏病的早期诊断。
New generation magnetocardiography uses a powerful medical device to detect weak current signals emitted by the cardiac muscle cells. The procedure is fast, simple and non invasive. Coupled with smart software, it allows the generation of current density vectors images revealing the electrophysiological state of the heart. Given its high sensitivity, this method allows detection of abnormal current symptomatic of cardiac conditions, at rest enabling early diagnosis of heart disease.
SQUIDs (超导体量子干涉装置)是最适合记录人类心脏电活动产生磁场的传感器。它们允许在空间和时间上精确测量在心脏活动期间流过心肌纤维的电流产生的极弱磁场。这些电流可以是轴向、切向和涡旋。心电图不能检测到涡流，因此Cardiomox的MCG-9能够唯一地检测到磁场的方向和大小，监测病人心脏的电生理活动，从而能够区别检测出心脏状况的异常电流症状。
SQUIDs (Superconductor quantum interference device) are the best-suited sensors to record the magnetic fields arising from the electrical activity of the human heart. They allow spatially and temporally accurate measurements of the very weak magnetic fields produced by currents flowing through the myocardial fibres during cardiac activity. These currents can be axial, tangential and vortex. Vortex currents are not detectable by ECG, as a result Cardiomox’s MCG-9 is able to uniquely detect the direction and magnitude of the field to monitor the electrophysiological activity of the patient’s heart allowing differential detection of abnormal current symptomatic of cardiac conditions.
分析软件是MGC在心脏病学应用中的一个主要障碍，这就是为什么Cardiomox能够将他们的研究范围扩大到MCG设备本身之外，他们不仅开发了分析数据的智能软件，而且还专注于鉴别诊断的可靠标记。
Analysis software has represented a major hurdle in the application of MGC to cardiology. This is why Cardiomox has broadened their research above and beyond the MCG device itself. Not only did they develop intelligent software to analyse the data but they have also focussed on identifying reliable markers allowing differential diagnosis.
为什么要使用我们的设备?
Why use our device?
SIMPLE, For patients the procedure is simple, fast and stress-free. Patient remain fully clothed as no preparation is required.
快速，有了这项技术，患者可以在10分钟内得到治疗，心脏科医生可以在几分钟内作出人工呼吸支持的诊断。FAST, With this technique patients can be processed within 10 min and an AI-supported diagnosis can be given by the cardiologist within minutes.
安全，该装置测量心脏磁场。不需要化学品和辐射，我们的程序是安全的，可以重复没有限制。这对于长期的病人护理特别有用。SAFE, The device measures the heart magnetic field. With no chemicals and no radiations required, our procedure is safe and can be repeated without restrictions. This is particularly useful for long-term patient care.
详实，Cardiomox的设备能够监测患者心肌细胞的电生理状态，并能动态监测电流的动量。INFORMATIVE, Cardiomox’s device mesures the electrophysiological state of the patients’ cardiac muscle cells and dynamically monitors the momentum of the currents.
改善患者的结果，有了先进的人工智能驱动软件来分析数据，你可以给病人一个快速的诊断。由于Cardiomox设备非常敏感，可以在疾病早期发现异常的心电生理微扰症状。有了早期诊断，该设备可以让心脏病专家在无需进一步核磁共振成像或血管造影的情况下改善患者的护理、治疗和预后。IMPROVED PATIENT OUTCOME, With a pioneering AI-driven software to analyse the data, you can give patients a quick diagnosis. As Cardiomox’s device is so sensitive, abnormal electrophysiological perturbations symptomatic of cardiac conditions can be detected at an early stage of the disease. With an early diagnosis, the device allows cardiologists to improve their patients’ care, treatment and outcomes without further MRIs or angiograms.
更好的病人体验，有一个快速，无创和无痛的程序预先在休息，检查是快速和没有漫长的准备;减少压力和并发症的风险。对于大多数心脏疾病来说，这项测试非常敏感，可以在休息时进行，而不是在运动时进行，这样可以节省时间，但更重要的是可以改善患者的体验。BETTER PATIENT EXPERIENCE, With a fast, non-invasive and painless procedure preformed at rest, the examination is rapid and without lengthy preparation; reducing both stress and risk of complications. For most heart conditions, the test is so sensitive it can be performed at rest rather than under exercise, which saves time but more importantly improves patient experience.
加快病人好转，Cardiomox的设备是临床应用的理想设备。在不到10分钟的时间内进行一次扫描，操作者可以每天评估至少20名患者，并在几分钟内为心脏病专家提供功能性诊断指南。FASTER PATIENT TURNAROUND, Cardiomox’s device is ideal for a clinical setting. With a single scan performed in less than 10 minutes, operators can evaluate at least 20 patients a day and provide a functional diagnostic guide for the cardiologist within minutes.
更高的效率，我们的创新提供了有效的筛选，区分心脏疾病和非心脏疾病，并评估其严重性。例如，is为心肌缺血、心律失常、冠状动脉疾病等提供了可靠的诊断。此外，它减少了对进一步侵入性和昂贵的诊断程序的需要，如血管造影和MRI。GREATER EFFICIENCY, Our innovation provides effective screening differentiating cardiac from non-cardiac diseases and assessing their severity. For example is provides a reliable diagnostic for myocardial ischemia, arrythmia, coronary artery disease etc. Furthermore, it reduces the need for further invasive and expensive diagnostic procedures such as angiography and MRI.
为了更好地进行合作和市场推广，以及售后服务和技术支持，我公司派驻了一名高级商务代表常驻英国，并在英国设立新的欧洲办事处，负责与牛津公司进行业务联系和对接合作事宜。此外，我公司还将不断从英国和欧洲范围内引进更多更先进的医疗技术和器械设备，促进中国和英国与欧洲在先进的医疗器械领域的交流与合作。
In order to better carry out cooperation and marketing, as well as after-sales service and technical support, our company appointed a senior business representative to the UK, and set up a new European office in the UK, responsible for business contact and cooperation with Oxford company. In addition, we will continue to introduce more and more advanced medical technology and equipment from the UK and Europe, and promote the exchanges and cooperation between China, the UK and Europe in the field of advanced medical equipment.
Ms. X LI
Director of London Office
Nanning Vesdomlly Business & Trade (UK) Ltd.